. Oxidative stress is believed to be critical in this disease pathogenesis [4] [5] [6] , although the exact mechanisms remain enigmatic. Protein S-glutathionylation (PSSG) is a post-translational modification of proteins that can be reversed by glutaredoxin-1 (GLRX) 7 . It remains unknown whether GLRX and PSSG play a role in lung fibrosis. Here, we explored the impact of GLRX and PSSG status on the pathogenesis of pulmonary fibrosis, using lung tissues from subjects with idiopathic pulmonary fibrosis, transgenic mouse models and direct administration of recombinant Glrx to airways of mice with existing fibrosis. We demonstrate that GLRX enzymatic activity was strongly decreased in fibrotic lungs, in accordance with increases in PSSG. Mice lacking Glrx were far more susceptible to bleomycin-or adenovirus encoding active transforming growth factor beta-1 (AdTGFB1)-induced pulmonary fibrosis, whereas transgenic overexpression of Glrx in the lung epithelium attenuated fibrosis. We furthermore show that endogenous GLRX was inactivated through an oxidative mechanism and that direct administration of the Glrx protein into airways augmented Glrx activity and reversed increases in collagen in mice with TGFB1-or bleomycin-induced fibrosis, even when administered to fibrotic, aged animals. Collectively, these findings suggest the therapeutic potential of exogenous GLRX in treating lung fibrosis.
Idiopathic pulmonary fibrosis (IPF) is associated with excess oxidative stress, and depletion of glutathione (GSH) in the lung-lining fluid, sputum and serum has been observed 5, 6, [8] [9] [10] . Depletion of GSH in the lung-lining fluid of subjects with IPF was first reported almost 30 years ago 8 , along with decreases in sputum and plasma GSH 9, 10 . The observations of low GSH levels in individuals with IPF prompted studies to administer the GSH precursor, N-acetyll-cysteine (NAC), to augment GSH in lung tissue 11 . Despite findings that NAC attenuated bleomycin-induced fibrosis in mice 12, 13 , and promising results with NAC in an initial clinical trial 14 , a subsequent clinical trial failed to demonstrate a therapeutic effect of NAC in subjects with IPF 15 . One facet of GSH biochemistry that to date has not been considered in the pathogenesis of IPF is protein S-glutathionylation (PSSG), the covalent attachment of glutathione to reactive protein cysteine residues. Given the impact of GSH adduction on the size and charge of target proteins, PSSG is emerging as a regulatory mechanism whereby an oxidant signal is transduced in a (patho) biological response 5, 16 . Under physiological conditions, glutaredoxin-1 (GLRX) deglutathionylates proteins, re-establishing the thiol group 7 . The extent to which GLRX and PSSG are affected in the setting of fibrosis remains unknown. We therefore determined whether GLRX and PSSG are altered in lung tissues from subjects with IPF. GLRX mRNA and protein were slightly but statistically significantly lower in lung tissues from subjects with IPF compared to non-IPF subjects (Fig. 1a,b and Supplementary Tables 1 and 2 ). However, immunoprecipitation of GLRX from lung tissues revealed strongly decreased GLRX enzymatic activity in IPF lung tissues, as compared to non-IPF controls, despite an equivalent input of the GLRX protein ( Fig. 1c and Supplementary Fig. 1a ). Consistent with the lower GLRX activity, PSSG was notably higher in individuals with IPF (Fig. 1d) . We also visualized patterns of PSSG in situ 17 , which also revealed strikingly higher reactivity in lung tissues from subjects with IPF, compared to non-IPF controls, and notably in cells resembling reactive type II epithelial cells ( Fig. 1e and Supplementary Fig. 1b) . Consistent with its role in deglutathionylation, an inverse correlation between GLRX activity and PSSG was apparent across all subjects (Fig. 1f) . Loss of GLRX and elevations in PSSG highly correlated with a lower diffusing capacity of carbon monoxide (DL CO ) and forced vital capacity across all subjects (Fig. 1g,h and Supplementary Fig. 1c,d) .
One target for PSSG important in pulmonary fibrosis is the death receptor FAS [18] [19] [20] through its role in augmenting epithelial apoptosis 19 . Epithelial cell apoptosis and impaired epithelial cell progenitor function are believed to be critical in fibrogenesis [21] [22] [23] . It is unknown whether FAS-SSG occurs in lungs of individuals with IPF and whether this correlates with disease parameters. Remarkably, 
Reducing protein oxidation reverses lung fibrosis
Vikas
Letters
NATuRe MedICINe in 17 out of 18 IPF subjects evaluated, we detected robust elevations in FAS-SSG, while in healthy lungs, we observed little to no detectable FAS-SSG ( Supplementary Fig. 1e,f) . Elevations in caspase-8 (CASP8) and caspase-3 (CASP3) activities were also apparent in lung tissues from subjects with IPF ( Supplementary  Fig. 1g,h ), consistent with previous findings 23 , and correlated with FAS-SSG ( Supplementary Fig. 1i ). FAS-SSG and CASP3 showed a negative correlation with baseline forced vital capacity and DL CO in subjects with IPF as compared to controls ( Supplementary  Fig. 1j-m) . Together, the lower GLRX activity and accompanying higher levels in PSSG, including FAS-SSG, in lung tissues from individuals with IPF and the observed correlations between these changes and reduced lung function suggest a role for GLRX and S-glutathionylation in the pathogenesis of lung fibrosis.
We next assessed the impact of global ablation of Glrx on the development of pulmonary fibrosis and showed that bleomycinor AdTGFB1-induced collagen deposition was greater in mice lacking Glrx, compared to wild-type (WT) littermates (Fig. 2a,b and Supplementary Fig. 2a,b) . As expected, elevations in overall PSSG and Fas-SSG induced by bleomycin or AdTGFB1 were more pronounced in mice lacking Glrx (Fig. 2c,d and Supplementary  Fig. 2c ), in association with greater activities of Casp3 ( Fig. 2e and Supplementary Fig. 2d ). The enhanced susceptibility to AdTGFB1-induced Casp3 activation and fibrosis observed in Glrx −/− mice was markedly lowered or absent in mice that were also Fas deficient (Lpr genotype; Supplementary Fig. 2a-d) , demonstrating that the augmented susceptibility to lung fibrosis in Glrx −/− mice is due to Fas and is closely linked to Fas-SSG.
Casp8 and Casp3 mediate degradation of Glrx and promote Fas-SSG and epithelial apoptosis 19 . Ablation of Casp8 in lung epithelial cells ( Supplementary Fig. 3a ) led to a robust attenuation of AdTGFB1-induced Casp8 and Casp3 activities in lung tissue ( Supplementary Fig. 3b ) and strongly attenuated AdTGFB1-induced Fas-SSG, fibrosis and mesenchymal gene expression ( Supplementary Fig. 3c-e) . Administration of adenovirus encoding Cre recombinase to Casp8 loxP/loxP mice before administration of bleomycin similarly resulted in lower Casp8 and Casp3 activities, Fas-SSG and fibrosis ( Supplementary Fig. 3f-h ), in association with Table 1 shows subject demographics. b, GLRX protein in lung tissues from individuals without IPF (non-IPF; n = 30) and with IPF (n = 29). c, GLRX enzyme activity following its immunoprecipitation from lung tissues from subjects with IPF (n = 16) and without IPF (non-IPF; n = 15). The results are expressed as nanomoles per minute per milligram of input protein. d, PSSG in lung tissue from cases of IPF (n = 30) and non-IPF (n = 30). e, In situ PSSG (red) in healthy lungs (n = 4) or lung tissue from subjects with IPF (n = 4). Nuclei are stained blue. Scale bar, 50 µ m. White arrowheads, reactive type II pneumocytes. f-h, Correlations between PSSG and GLRX activity (f), PSSG and DL CO (g) and GLRX activity and DL CO (h) in the lungs of subjects with IPF and non-IPF controls. Supplementary Table 2 shows demographics of the subject samples used in b-h. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student's t-test. Error bars, s.e.m. (× 1,000 ). e, Casp3 activity in lungs from WT or Glrx −/− mice 21 d post bleomycin (n = 5 mice per group) pooled from 2 independent experiments. f-j, Attenuation of bleomycin-or AdTGFB1-induced fibrosis, PSSG and Casp3 activation in mice overexpressing Glrx in airway epithelia (Epi-Glrx) compared to WT or Ctr groups. Shown are total PSSG (f; n = 5 mice per group), Fas-SSG (g, top), Casp3 activity (h; n = 5 mice per group) and collagen content (i; Sircol; WT PBS, n = 5; WT BLM, n = 8; Ctr PBS, n = 4; Ctr BLM, n = 5; Epi-Glrx PBS, n = 5; Epi-Glrx BLM, n = 7 (mice per group)) in lung tissues. g, Bottom, assessment of Fas-SSG in Ctr or Epi-Glrx transgenic mice that received AdTGFB1 or Ad-Ctr. Flag-GLRX (asterisk) confirms transgene expression. Representative blots reflect n = 3-4 mice per group. Ctr, CCSP-rtTA single-transgenic mice fed doxycycline. j, Hydroxyproline in lungs from CCSP-rtTA/TetOP-Glrx bitransgenic mice following delayed administration of doxycycline (Ctr, n = 5; TGFB1, n = 8 (mice per group)). Shown are cropped western blots. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA using Tukey's post hoc test. Error bars, s.e.m.
NATuRe MedICINe elevated mRNA expression of Cdh1 and lower expression of Vim and Acta2 mRNA (encoding E-cadherin, vimentin and alpha-smooth muscle actin, respectively; Supplementary Fig. 3i ). Collectively, these findings support the contribution of epithelial Casp8 in elevating Fas-SSG, impairing epithelial restitution and enhancing fibrogenesis. These findings are in line with previous studies documenting that epithelial apoptosis 20, 21, 24 and loss of epithelial progenitor function 22 are critical drivers in the pathogenesis of pulmonary fibrosis and strongly suggest that PSSG amplifies apoptosis.
Enhanced expression of GLRX leads to protein deglutathionylation and protects epithelial cells from apoptosis 19 . To address the impact of elevated expression of Glrx for the development of fibrosis, we created mice with the TetOP-Glrx transgene, which were crossed with CCSP-rtTA mice to express Glrx in lung epithelial cells 25 . Mice expressing Glrx in the lung epithelium exposed to bleomycin showed diminished PSSG (Fig. 2f) and Fas-SSG (Fig. 2g , top) in lungs compared to WT littermates or mice with only the CCSP-rtTA transgene (Ctr). Furthermore, the bleomycin-mediated elevations in Casp3 activity (Fig. 2h) and fibrosis (Fig. 2i) were also lower in Glrx transgenic mice, as compared to the Ctr groups. We next delayed administration of doxycycline-containing chow to CCSP-rtTA/TetOP-Glrx transgenic mice until 14 d after administration of AdTGFB1, a time point when elevations in collagen have been reported 26 . Delayed expression of epithelial Glrx still led to lower Fas-SSG (Fig. 2g, bottom) and fibrosis compared to the Ctr group, when evaluated 10 d thereafter (Fig. 2j) .
We next determined whether direct administration of recombinant WT Glrx ( Fig. 3a and Supplementary Fig. 4a -c) into airways of mice with existing fibrosis affected disease progression. Direct administration of WT Glrx into lungs of control mice resulted in elevations of Glrx in alveolar regions, with higher fluorescence also being observed within bronchial epithelia and cells within airspaces ( Fig. 3b and Supplementary Fig. 5 ). Administration of Glrx (6 µ g every third day) into airways of mice with existing bleomycin-induced fibrosis restored the attenuated Glrx activity (Fig. 3c ) and reversed elevations in PSSG (Fig. 3d) . Administration of Glrx reversed the bleomycin-mediated elevations in hydroxyproline over the next 13 d (Fig. 3e ) and elevated pyridinoline cross-links ( Fig. 3f) , indicative of enhanced degradation of collagen fibers. Glrx led to a reversal of the bleomycin-mediated elevations of hydroxyproline in a dose-dependent manner (Fig. 3g ). Histopathological assessment of collagen fibers in parenchymal regions showed that Glrx attenuated the elevations in collagen induced by bleomycin at day 28, although some elevations in collagen and distortions in the tissue were still apparent within this time frame (Fig. 3h,i) . We next administered Glrx into lungs of mice 21 d post administration of AdTGFB1 (Fig. 3j,k) , a time point when higher levels of hydroxyproline were detected (Fig. 3k) . Administration of WT Glrx for the next 3 weeks reversed the elevated levels of hydroxyproline to control levels (Fig. 3k) . In contrast, mutant Glrx lacking the N-terminal cysteine required for deglutathionylating activity (Glrx C23S; Supplementary Fig. 4b ) did not attenuate fibrosis (Fig. 3k ).
Glrx has previously been shown to be inactivated via oxidation of structural cysteines outside the active site 27 . In mice with bleomycin-induced fibrosis or lungs from subjects with IPF, GLRX was S-glutathionylated ( Supplementary Fig. 6a,b) . S-glutathionylation of GLRX coincided with loss of activity and a higher PSSG content in lung tissue, suggesting that elevations in GLRX-SSG do not reflect catalytic activity, during which Cys23 of GLRX is transiently S-glutathionylated 7 , but instead point to oxidative inactivation. ELISAs run under non-reducing conditions showed slightly less immunoreactive GLRX in lungs from IPF subjects (Fig. 1b) or no change in lungs from mice with bleomycin-induced fibrosis ( Supplementary Fig. 7a ). However, in the presence of dithiothreitol (DTT), we detected slightly more immunoreactive GLRX in bleomycin-injured mice or subjects with IPF compared to the respective control groups ( Supplementary Fig. 6a,b) , suggesting that, in settings of fibrosis, GLRX was oxidatively modified. In support of this possibility, the loss of Glrx enzymatic activity in mice with bleomycininduced fibrosis could be partially reversed by DTT ( Supplementary  Fig. 6c ). Furthermore, direct administration of glutathione disulfide to recombinant Glrx resulted in S-glutathionylation of Glrx and a concomitant loss of enzymatic activity ( Supplementary  Fig. 6d ), demonstrating that S-glutathionylation can result in inactivation of Glrx.
Pulmonary fibrosis manifests in individuals 55 years and older in age, suggesting that IPF is a disease associated with ageing 28, 29 . Redox mechanisms have been implicated in age-related pulmonary fibrosis 6 . We therefore addressed whether lower Glrx activity and higher PSSG levels were associated with the age-dependent enhanced susceptibility to pulmonary fibrosis. Compared to 3-month-old mice, Glrx activity was lower in lungs from 18-or 24-month-old mice (Fig. 4a) , whereas PSSG was slightly but not significantly elevated with age in naive animals (Fig. 4b) . Bleomycin-induced fibrosis is enhanced and persistent in aged mice 30 . The lowered Glrx activity induced by bleomycin in 3-month-old mice was more pronounced in 18-month-old animals ( Fig. 4c ) and correlated with higher hydroxyproline content in lungs from 18-month-old as compared to 3-month-old mice exposed to bleomycin (Fig. 4d ). Overall Glrx levels showed only slight changes with age in naive mice or following administration of bleomycin ( Supplementary Fig. 7a ). Similarly, GLRX mRNA was marginally affected with age in healthy human lungs or in subjects with IPF, although a slight inverse correlation was detected between GLRX mRNA and increasing age in subjects with IPF ( Supplementary Fig. 7b ,c). Overall these findings suggest that the age-associated dysregulation of Glrx predominantly occurs post-translationally. Administration of recombinant Glrx into airways of 18-month-old animals starting 21 d post administration of bleomycin led to higher Glrx activity in lung tissue, lower PSSG and lower collagen content evaluated 21 d later (Fig. 4e-g ), along with lower mRNA expression of Vim and Acta2, higher expression of Cdh1 (Fig. 4h ) and lower Casp3 activity (Fig. 4i) . C23S mutant Glrx did not affect Glrx activity nor PSSG in lung tissue (Fig. 4e,f) , marginally affected Cdh1, Acta2 and Vim expression (Fig. 4h) and did not affect Casp3 activity (Fig. 4i) . In line with the findings in Fig. 3k , mutant Glrx did not affect hydroxyproline in aged mice with bleomycin-induced fibrosis (Fig. 4g) , demonstrating that the catalytic activity of Glrx is required for its ability to attenuate pulmonary fibrosis. Glrx-mediated attenuation of Vim and Acta2 mRNAs along with elevations in Cdh1 suggests restoration of epithelial-mesenchymal balance but does not address how Glrx reverses existing fibrosis. We therefore addressed the collagen-degrading activity of lung tissues treated with Glrx. WT Glrx (but not mutant Glrx) led to activation of collagenase activity in aged mice with bleomycin-induced fibrosis ( Fig. 4j and Supplementary Fig. 8a,b) . These findings, along with the Glrx-mediated elevation in pyridinoline cross-links (Fig. 3f) , suggest a potential impact of Glrx on promoting degradation of the extracellular matrix.
Pulmonary fibrosis is an unrelenting progressive disease, associated with enhanced epithelial cell death, impaired epithelial progenitor function and consequently failure to restore normal epithelial barriers 22, 29, 31 . These processes are believed to stimulate an overpopulation of activated myofibroblasts and excessive deposition of extracellular matrix 32 . Current therapies have limited effectiveness to halt disease progression, which typically results in the death of subjects with IPF within 3-5 years from the time of diagnosis 3, 33, 34 . As was mentioned above, changes in glutathione redox homeostasis were first observed in subjects with IPF over 20 years ago 8, 10 , yet a recent clinical trial with NAC showed no clear therapeutic benefit in subjects with IPF 15 . The present findings differ substantially from the previous observations. Unlike NAC, Glrx cannot be considered a nonspecific antioxidant, but rather is a member of a larger family of thiol disulfide . Shown are data pooled from two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA using Tukey's post hoc test. NS, not significant. Error bars, s.e.m.
NATuRe MedICINe oxidoreductases that regulates the oxidation state of protein thiols 7, 35 . Alterations in protein thiol redox homeostasis occur in response to specific oxidative events, in a compartmentalized fashion, and affect select amino acid residues 16 . Recent studies demonstrated that pharmacologic inhibition of non-phagocytic oxidase-4 (NOX4) reversed pulmonary fibrosis in aged mice 30 . NOX4 has been shown to produce H 2 O 2 in the endoplasmic reticulum (ER) 36 and to promote epithelial cell death during the development of bleomycin-induced fibrosis 37 . Our previous work showing that Fas-SSG occurred in association with ER redox perturbations 38 points to a potential role for ER-linked oxidative processes in pulmonary fibrosis 31 . Furthermore, dysregulation of mitochondrial homeostasis and associated increases in reactive oxygen species have been implicated in pulmonary fibrosis 39, 40 . PSSG observed herein could be a potential consequence of NOX4-or mitochondrially derived oxidants, although additional studies will be required to address these possibilities. PSSG has emerged as an oxidant-dependent post-translational modification of reactive protein cysteines that changes structure and function, and serves as a platform for GLRX-dependent restoration 5, 7 . Herein, we demonstrate that the PSSG-GLRX redox axis is markedly altered in subjects with IPF and in multiple mouse models of fibrosis, on the basis of the observed elevations in PSSG and inactivation of GLRX.
The exact mechanistic details of inactivation of GLRX in settings of fibrosis are unclear. The present study shows that Glrx is . Shown are pooled data from two independent experiments. h, Gene expression of Vim, Acta2 and Cdh1 in lung tissue (HBSS, n = 5; WT Glrx, n = 8; Mut Glrx, n = 7 (mice per group)). Data are expressed relative to mice exposed to PBS at 21 d. i, Casp3 activity (n = 6 mice per group). RLU, relative luminescence units. j, Collagen-degrading activity in lung lysates (n = 3 mice per group form a single analysis). Additional information is provided in Supplementary Fig. 8a ,b. M, marker; PC, positive control using collagen plus recombinant collagenase; NC, negative control (rat tail collagen). α , β and γ are the subunits of collagen. The bulky arrows indicate degradation products. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA using Tukey's post hoc test. NS, not significant. Error bars, s.e.m.
NATuRe MedICINe oxidatively inactivated in association with S-glutathionylation, on the basis of the demonstration that the reducing agent DTT partially restores the catalytic activity of Glrx immunopurified from fibrotic tissue and that direct S-glutathionylation of recombinant Glrx inhibits its enzymatic activity ( Supplementary Fig. 6c,d ). The tissue-protective effect of exogenously administered Glrx may therefore be linked to the rescue of endogenous Glrx, as suggested by rapid enhancement of Glrx activity in lung tissues even after a single administration of Glrx (Fig. 3c) . However, additional studies will be required to formally test that scenario. Further studies will also be required to elucidate the nature of inactivation of GLRX in lungs from subjects with IPF. Similarly, the S-glutathionylated proteins that are targets for GLRX-mediated reduction during resolution of fibrosis and the cell types and locations in which they occur will also require further investigation. The impact of Glrx on attenuating S-glutathionylation of Fas and associated decreases in epithelial cell death 19 , along with the Glrx-mediated stimulation of collagen-degrading activity, suggest that Glrx exerts antifibrotic effects through multiple independent mechanisms. The present findings demonstrating that administration of recombinant Glrx into airways reverses existing fibrosis in aged mice, along with the observations that GLRX is inactivated in lungs from subjects with IPF, suggest a potential novel treatment modality to halt progression of this devastating disease.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0090-y. 
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Methods Animals. For all experiments, age-matched male and female mice (C57BL6/NJ) were used. Bitransgenic mice expressing the reverse tetracycline transactivator transgene from the club cell secretory protein promoter (CCSP-rtTA) plus Cre recombinase from the tetracycline operon (TetOP-Cre) were provided by J. Whitsett (University of Cincinnati) 41, 42 . 25 . The single-transgenic littermates containing either CCSP-rtTA or TetOP-FLAG Glrx alleles (labeled as Ctr) fed doxycycline were used as controls in the experiments. To overexpress Glrx, all mice were maintained on doxycycline-containing chow starting from 7 d before the instillation of bleomycin. Mice were euthanized 21 d post administration of bleomycin. In selected experiments involving AdTGFB1, doxycycline-containing chow was withheld until 14 d after administration of AdTGFB1, and thereafter mice were maintained on doxycycline-containing chow for an additional 10 d until euthanasia. Fas-deficient (Lpr) mice 44 and Glrx-deficient (Glrx −/− ) mice were described previously 45 and used to generate Lpr/Glrx −/− double knockouts. Unmanipulated 3-, 18-and 24-month-old mice were euthanized, and lungs were removed for the assessment of Glrx activity and PSSG content. Eighteen-monthold C57BL/6 mice were obtained from the National Institute of Aging (NIA) and subjected to bleomycin-induced fibrosis. All animal use and treatment protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of UVM.
Mouse models of fibrosis and administration of Glrx. Bleomycin (5 U kg
body weight, APP Pharmaceuticals) or 5 × 10 8 PFU AdTGFB1 223/225 (provided by J. Gauldie, McMaster University) was administered oropharyngeally, as described previously 17, 38 . PBS or Ad5 adenovirus (Ad-Ctr, Vector Biolabs) was administered as a respective control. In selected experiments, recombinant Glrx proteins were administered oropharyngeally to mice at various times post administration of AdTGFB1 or bleomycin, as follows. At 14 d post administration of bleomycin to 2-to 4-month-old mice, some animals were euthanized to confirm fibrosis. The remaining animals received 6 μ g Glrx oropharyngeally up to 5 times (that is, Glrx 1× to 5× ), administered 3 d apart. Three mice per group were euthanized at 16 h post administration of Glrx on day 15, 18, 21, 24 or 27. As a control, mice received 5 administrations of HBSS and were euthanized on day 27 (+ HBSS 5× ). A separate dose-response study was carried out in which the Glrx administration dose was varied, ranging from 1 to 12 µ g of protein administered once every third day starting on day 14 post administration of bleomycin. Mice were euthanized on day 24.
Alternatively, mice were administered AdTGFB1 or AdCtr, and 21 d thereafter received either HBSS (vehicle), WT Glrx (6 μ g) or C23S Glrx (6 μ g) once every third day. Mice were euthanized at day 42 for assessment of hydroxyproline. In 18-month-old mice that received bleomycin, Glrx or HBSS, administration was delayed until 3 weeks post bleomycin, to address the impact of Glrx on existing fibrosis, and mice were euthanized on day 42. A dose of 6 µ g of Glrx (with the exception of the dose-response study) was administered to 2-to 4-month-old adult mice, while a dosing regimen with 12 μ g was used in 18-month-old mice, corresponding to approximate doses of 250 μ g kg −1 body weight.
Human subjects. Deidentified formalin-fixed paraffin-embedded or frozen lung tissue from subjects diagnosed with IPF on the basis of appropriate clinicalradiographic features and usual interstitial pneumonia on histopathologic examination or normal tissues were obtained from the National Institutes of Health Lung Tissue Research Consortium or from the Department of Pathology and Laboratory Medicine, University of Vermont. Demographics of the study population are provided in Supplementary Table 1 . The Institutional Review Board at the University of Vermont certified that the study did not constitute human subjects research. The Lung Genomics Research Consortium (LGRC) cohort 46 was used to determine expression of the GLRX gene. Expression of the GLRX gene was measured at the probe level (probe ID: A_23_P69908), from the Agilent-014850 Whole Human Genome Microarray 4× 44K G4112F (Agilent), used in the LGRC cohort as previously described 46 . Data from individuals with IPF and controls were used for this analysis. The gene expression data are available from the GEO database (http://www.ncbi.nlm.nih.gov/geo/) under the accession GSE47460. R software (2.12.2) was used for GLRX expression analysis 47 . The R stats package version 3.0.1 was implemented. GLRX gene expression in lung tissue was available for 160 individuals with IPF and 132 controls from the LGRC cohort; demographic and physiological characteristics are presented in Supplementary  Table 2 . Differences in sex composition were seen between individuals with IPF and controls (69% versus 50% males, respectively). Given this sex imbalance, a linear model was used to control for the effect of sex in GLRX gene expression between the two conditions. Sex did not have an effect on GLRX expression in this model. To address whether GLRX expression changes in normal human lung with age, RNA-seq data from the Broad Institute's Genotype-Tissue Expression (GTEx) Project were analyzed (GTEx Analysis V6p; http://www.gtexportal.org/ home/datasets; file: GTEx_Analysis_v6p_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm. gct.gz). Applying custom Perl scripts (perl v5.18.2), data from 320 normal human lung samples were parsed and assigned corresponding age bins and sex values based on separate sample annotation files (see the URL above; file: GTEx_Data_ V6_Annotations_SampleAttributesDS.txt; file: GTEx_Data_V6_Annotations_ SubjectPhenotypesDS.txt). Gene expression data for GLRX (ENSG00000173221.9), reported as reads per kilobase of transcript per million mapped reads, were extracted for each sample using a second custom Perl script, followed by statistical analysis (linear regression analysis or the Kruskal-Wallis test) in Prism v7.0a.
Assessment of fibrosis.
Lung sections were stained with Masson's trichrome reagent to stain collagen. Lung sections were imaged using an Olympus BX50 Light Microscope with a QImaging Retiga 2000R digital camera. Total lung collagen was measured in the right middle lobe of the lung after overnight digestion with 10 mg ml −1 pepsin in 0.5 M acetic acid using the Sircol assay (Biocolor) as directed by the manufacturer. Hydroxyproline content was assessed in the right superior lung lobe 48 . The amount of collagen in tissue sections was quantified using picrosirius red and imaging under polarized light 49 . Paraffin-embedded whole lung tissues (5-µ m sections) were processed and stained in 0.1% sirius red F3BA (Pfaltz & Bauer, S03695) in saturated picric acid. Monochromatic images were taken using an Olympus SZX12 dissecting microscope, to reduce selection bias. Square grids were randomly generated to select ten parenchymal regions. Grids containing edges, blank spaces, airways or debris were disregarded. Images of thus randomly selected regions were acquired using an Olympus BX50 light microscope at × 20 magnification with circularly polarized light (Olympus). Overall collagen content was assessed using MetaMorph software 49 . The data are expressed as a ratio of the colored pixels representing collagen fibers to the total area and reflect the average of ten images per animal.
Western blot analysis. Lung tissues were lysed in buffer containing 20 mM Tris-HCl (pH 7.5), 130 mM NaCl and 1% NP-40 or 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.2% SDS, 0.5% Triton X-100 and 0.5% NP-40 with 20 mM N-ethyl maleimide (NEM). Samples were pelleted via centrifugation, and following protein quantification of the supernatant, samples were resuspended in loading buffer with DTT and resolved by SDS-PAGE. Proteins were transferred to PVDF, and membranes were probed using a standard immunoblotting protocol using the following primary antibodies: FAS (Millipore, BD Biosciences), GLRX (Virogen) and β -actin (Sigma). Uncropped western blots are provided in Supplementary Figs. 9-13 . Densitometric analysis. Densitometric analyses were performed utilizing Bio-Rad VersaDoc Imager Software. Western blot X-ray films were imaged, and rectangles of identical size were traced around each band and assessed for density (intensity mm −2 ). Values were normalized to corresponding β -actin bands following background subtraction.
Quantitative RT-PCR for epithelial and mesenchymal markers. RNA was extracted, treated with DNAse using RNEasy columns (Qiagen) and reversetranscribed into cDNA using MMLV RT (Gibco-BRL) according to the manufacturer's instructions. Mesenchymal (Vim and Acta2) and epithelial (Cdh1) gene expression was determined by quantitative real-time PCR using an Applied Biosystem CFX1000 with 25 ng of cDNA per reaction and SYBR green for individual target genes. Relative expression was normalized using the expression of cyclophilin mRNA by the Δ Δ Ct method. Primer sequences and accession codes are as follows: vimentin (Vim, gene ID: 12550) fwd: 5′ -TGAAGGAAGAGATGGCTCGT-3′ , rev: 5′ -TCCAGCAGCTTCCTGTAGGT-3′ , alpha-SMA (Acta2, gene ID: 11475) fwd: 5′ -CGCTGTCAGGAACCCTGAGA-3′ , rev: 5′ -CGAAGCCGGCCTTACAGA-3′ and E-cadherin (Cdh1, gene ID: 12550) fwd: 5′ -ACTGTGAAGGGACGGTCAAC-3′ , rev: 5′ -GGAGCAGCAGGATCAGAATC-3′ .
Production of recombinant GLRX and assessment of GLRX activity. Mouse Glrx was subcloned into the PGEX-2T vector (GE Healthcare). N-terminal Cys23 was mutated to serine, using site-directed mutagenesis (Agilent). Both constructs were verified by sequencing. Both constructs were grown in BL21 Gold competent Escherichia coli (GE Healthcare). Glrx-GST was isolated using GSH-Sepharose affinity purification (Sigma). After removal of the GST tag with thrombin (Sigma), lipopolysaccharide was removed via endotoxin removal columns (Sigma). The purity of the final product was confirmed via Coomassie blue gels. The enzymatic activity of Glrx was determined in a reaction mix containing 137 mM Tris-HCl (pH 8.0), 0.5 mM GSH, 1.2 units GSSG reductase (Roche), 0.35 mM NADPH, 1.5 mM EDTA (pH 8.0) and 2.5 mM Cys-SO 3 . The reaction was allowed to proceed at 30 °C, and NADPH consumption was followed spectrophotometrically at 340 nm. Data are expressed as units, where 1 unit equals the oxidation of 1 μ M NADPH per minute per milligram of protein 50 . In experiments designed to address the direct impact of S-glutathionylation on the enzymatic activity of Glrx, Glrx was incubated with 50 mM GSSG at 37 °C for 30 min, following removal of excess GSSG using Micro BioSpin 6 Columns (Bio-Rad). The enzymatic activity of reduced or oxidized Glrx was then evaluated in a reaction mix containing 137 mM Tris-HCl (pH 8.0), 0.5 mM GSH, 1.2 units GSSG reductase (Roche), 0.35 mM NADPH, 1.5 mM EDTA (pH 8.0) and 20 μ M dieosin glutathione disulfide 51 . The secondary structures of WT and C23S Glrx were evaluated via circular dichroism (CD) spectroscopy. Samples were prepared in Dulbecco's PBS (2.7 mM KCl, 138 mM NaCl, 1.5 mM KH 2 PO 4 , 8.06 mM Na 2 HPO 4 , pH 7.4). CD spectral data were collected in the range from 250 to 195 nm using a Jasco J-815 spectropolarimeter with a scan rate of 20 nm min −1 , a bandwidth of 1.0 nm, and an integration time of 8 s. The CD data acquired in the range from 250 to 200 nm were analyzed by the program Beta Structure Selection (BeStSel) to investigate the secondary structure of each variant. The reported error estimates represent the r.m.s. deviation between secondary structure contributions measured using X-ray crystallography and those estimated from BeStSel analysis of the CD spectra for a reference dataset of 73 proteins 52 . CD analysis confirms that the secondary structure of Glrx in aqueous solution is essentially unchanged by the C23S substitution, and functional differences between the two variants must arise from a C23S-induced change to a different fundamental property of the protein. Recombinant WT Glrx was labeled with Alexa Fluor 647 (Invitrogen), and its distribution in lung tissue was determined 18 h post-oropharyngeal administration. Fresh-frozen lung sections were prepared, and the presence of labeled Glrx was detected via confocal laser scanning microscopy (Zeiss).
In select experiments, lung tissues were homogenized in lysis buffer containing 0.137 M Tris-HCl, 0.13 M NaCl and 1% NP-40, and Glrx was immunoprecipitated, using anti-GLRX antibody (Virogen). The activity of immunoprecipitated Glrx was determined as described above. To verify that equal amounts of Glrx were utilized, western blots were performed on immunoprecipitated samples. To address whether Glrx was inactivated via an oxidative mechanism, Glrx was immunoprecipitated from lung tissues and samples were incubated with 500 µ M DTT for 30 min at room temperature. Samples were washed in buffer containing 0.137 M Tris-HCl, 0.13 M NaCl and 1% NP-40, then washed in buffer containing 0.137 Tris-HCl, 0.5 M NaCl and 0.1875 EDTA, and GLRX activity was assessed as described. Results are expressed as nanomoles per minute per milligram of input protein.
As a control, preimmune IgG was used instead of GLRX-specific antibody, and background values obtained were subtracted.
Caspase assays. Lung tissues were homogenized and Casp3 and Casp8 activities were measured using Caspase-Glo assay kits (Promega). Data are expressed as arbitrary units after normalization to protein content.
In situ detection of PSSG. PSSG was detected in situ in paraffin-embedded lung tissues, following deparaffinization, rehydration and permeabilization of tissues in the presence of the thiol-blocking reagent NEM. Slides were next incubated with streptavidin to block endogenous biotinylated proteins. Specimens were thereafter subjected to Glrx-catalyzed cysteine derivatization, by incubating tissues in a reaction mix containing Glrx, GSSG reductase, GSH and NADPH for 30 min at room temperature 17 . Slides were washed and incubated with biotin-conjugated NEM followed by reaction with Alexa Fluor-conjugated streptavidin. As a control, replicate slides were incubated with a reaction mix lacking Glrx. Any resultant background reactivity was subtracted from labeling observed in the presence of Glrx. Images were acquired using a Zeiss LSM 510 META Confocal Laser Scanning Imaging System. Images were captured at × 40 magnification in oil immersion. The image files were converted to Tiff format using Adobe Photoshop CS5. Brightness and contrast were adjusted equally in all images. Fluorescent images in Fig. 1 were quantified using ImageJ software. For assessment of PSSG (red), three regions were randomly selected per subject and intensity values were pooled from non-IPF and IPF samples (n = 4). These values were normalized to the intensity of DAPI (blue, nuclei).
Detection of overall PSSG, FAS-SSG and GLRX-SSG.
Overall PSSG in lung tissue was assessed quantitatively following tissue homogenization, precipitation of proteins with 0.6% sulfosalicylic acid and release of GSH with 1% NaBH 4 . GSH was quantified using the 5,5′ -dithio-bis(2-nitrobenzoic acid) (DTNB)-GSSG reductase recycling method 53 . To detect S-glutathionylation of FAS or GLRX, lung lysates were prepared (50 mM Tris, pH 7.4, 150 mM NaCl, 0.25% SDS, 1% NP-40, 0.5% CHAPS and 20 mM NEM with protease inhibitor cocktail (Sigma-Aldrich)), and protein content was equalized. Anti-glutathione antibody (2 µ g ml
; American Diagnostica) was added to immunoprecipitate S-glutathionylated proteins using protein G agarose beads. Samples were analyzed by immunoblotting using anti-FAS (Millipore) or anti-GLRX (Virogen) antibodies. As a control, a portion of the lysate was treated with 50 mM DTT to reduce glutathionylated proteins, and these samples were purified through columns (Bio-Rad) to remove DTT before subsequent immunoprecipitation.
Assessment of collagen-degrading activity. Lung lysates (2.5 µ g) were individually incubated with 50 µ g of collagen type I (354236, Corning) in a total reaction volume of 40 µ l with Tris-HCl buffer (0.01 M; pH 7.4) at 37 °C for 24 h. The reaction was terminated by adding 20 µ l of sample buffer containing 4% SDS, 0.25 M DTT and 1 M urea and boiled for 7 min. Samples were loaded onto 7.5% SDS-polyacrylamide gels. Gels were stained with Coomassie brilliant blue R-250 (0.25%) to visualize the bands. Collagen alone incubated without lung lysates served as a negative control and collagen incubated with 2.5 µ g of standard purified collagenase (C8176, Sigma) served as a positive control for the collagenolytic activity. The quantification of protein expression was performed by densitometry using ImageJ software (https://imagej.nih.gov/ij/). In addition, lung tissues were hydrolyzed with 6 M HCl overnight at 110 °C. Lysates were cooled and then neutralized utilizing NaOH. Samples were assayed for pyridinoline content, according to the manufacturer's instructions (Quidel). The results are expressed as nanomoles of pyridinoline per milligram of protein.
Image processing. Digital images were acquired by scanning X-ray film on a photo scanner (perfection 5000; EPSON). Photoshop (CS5; Adobe) and Illustrator (CS5; Adobe) were used to assemble the figures. Samples were run on the same gel. In some cases, lanes were assembled for consistency as indicated by a vertical black line. When required, brightness and contrast were adjusted equally in all lanes.
Statistics.
Data from mouse studies were analyzed by one-way ANOVA using Tukey's test to adjust for multiple comparisons. The two-tailed Student's t-test was used when comparisons were made between two experimental groups. The center values of all plots represent mean values, and the error bars represent the s.e.m. With the exception of studies using Casp8 loxP mice involving bleomycin and Adeno-Cre ( Supplementary Fig. 3f -i) and collagenase activity (Fig. 4j) , all experiments were repeated at least once in separate groups of mice. Data from multiple independent experiments were averaged. The total animal numbers in each group are denoted in each figure legend. Random samples from two experiments were selected for biochemical (PSSG, western blots, collagen degradation gels and caspase assays) and mRNA analyses. Human data are presented as mean ± s.d. or median [interquartile range] and were analyzed with unpaired t-tests. GLRX expression was evaluated using the Kruskal-Wallis test. The P value for GLRX represents probe-level statistics unadjusted for multiple comparisons. Correlation plots for GLRX expression and age in IPF and control lungs were generated with the R ggplot2 package, and Spearman correlation coefficients were determined. Correlations between lung function and western blot densitometry data were performed using Pearson correlation coefficients on combined IPF and non-IPF subject groups. Subject quality of life was assessed by the St George's Respiratory Questionnaire 54 . The data were analyzed using JMP Pro 10 (SAS Institute, Inc.) and GraphPad Prism (Version 7.04). P values < 0.05 were regarded as statistically significant. No data were excluded from the analyses.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Lung Genomic Research Consortium cohort data were analyzed GSE47460 Geo database, Analyzed by R software (Version 3.0. For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Transgenic mice and other unique reagents are available upon request, upon completion of a material transfer agreement, per University of Vermont policy. Recombinant wild type and mutant Glutaredoxin proteins are not available due to a patent and commercialization licensing (Patent no. 8,679,811).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). The GLRX antibody were validated in transgenic and knock-out mice. The PSSG assay was validated through omission of GLRX. The GSH antibody was validated in Glrx transgenic and Glrx knockout mice, and via the inclusion of dithiothreitol.
